united healthcare glp-1 coverage weight loss Designing fiscally viable of weight-loss drugs Why we are changing coverage
Description
doi: 10.1016/j.cmet.2008.12.004
How could they not
Overall effects GLP1-RA treatment is associated with a 37% increase in gallbladder or biliary diseases compared with placebo
Molecular Mechanisms by Which GLP-1 RA and DPP-4i Induce Insulin Sensitivity
If Wegovy is covered and Zepbound isn't, you'll need prior authorization to switch, often requiring documentation that Wegovy failed or caused intolerable side effects
Bottom line: Stick with FDA-approved products from licensed pharmacies
